Eli Lilly Partners With Walmart To Expand Access To Popular Weight-loss Drug

• Zepbound vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November. 
• This marks LillyDirect’s first retail collaboration and is aimed at offering patients flexibility in how they access the drug, the company said.
  

Eli Lilly and Company (LLY) on Wednesday announced a collaboration with Walmart Inc. (WMT) to expand access to lower pricing for its popular weight-loss drug Zepbound, available through its digital health platform LillyDirect.

Zepbound vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November, the company said. This marks LillyDirect’s first retail collaboration and is aimed at offering patients flexibility in how they access the drug, the company said.

Zepbound single-dose vials will be available in all approved strengths, with the lowest dose starting at $349 per month with self-pay at Walmart pharmacies, the company said.

Zepbound, containing Tirzepatide, reduces appetite and the amount a person eats to induce weight loss. Lilly started offering Zepbound at discounted prices to cash-paying customers on LillyDirect in June to expand access. 

Get updates to this developing story directly on Stocktwits.<